Company profile

Ticker
PRGO
Exchange
Website
CEO
Murray S. Kessler
Employees
Incorporated
Location
Fiscal year end
Former names
PERRIGO Co Ltd
SEC CIK

PRGO stock data

(
)

Calendar

5 Aug 20
25 Oct 20
31 Dec 20

News

Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Perrigo earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
14 Aug 20 Robert Willis Ordinary Shares Payment of exercise Dispose F No 53.4 303 16.18K 2,055
14 Aug 20 Robert Willis Ordinary Shares Option exercise Aquire M No 53.4 581 31.03K 2,358
14 Aug 20 Robert Willis RSU Ordinary Shares Option exercise Dispose M No 0 581 0 1,160
12 Aug 20 Katherine C. Doyle RSU Ordinary Shares Grant Aquire A No 0 5,637 0 5,637
11 Aug 20 Svend Andersen Ordinary Shares Buy Aquire P No 53.0093 2,828 149.91K 10,028
29 Jun 20 Kingma Todd W Ordinary Shares Payment of exercise Dispose F No 54.56 1,303 71.09K 39,395
29 Jun 20 Kingma Todd W Ordinary Shares Option exercise Aquire M No 54.56 2,987 162.97K 40,698
29 Jun 20 Kingma Todd W RSU Ordinary Shares Option exercise Dispose M No 0 2,987 0 0
81.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 337 324 +4.0%
Opened positions 46 44 +4.5%
Closed positions 33 63 -47.6%
Increased positions 133 111 +19.8%
Reduced positions 104 112 -7.1%
13F shares
Current Prev Q Change
Total value 6.14B 8.89B -31.0%
Total shares 111.04M 111.17M -0.1%
Total puts 939.6K 636.1K +47.7%
Total calls 1.25M 628.4K +99.3%
Total put/call ratio 0.8 1.0 -25.9%
Largest owners
Shares Value Change
N Price T Rowe Associates 19.43M $1.07B -4.9%
Vanguard 16.03M $885.83M -1.0%
BLK BlackRock 9.98M $551.72M +1.8%
STT State Street 6.36M $351.47M +2.9%
BEN Franklin Resources 4.37M $246.8M -3.3%
Brown Brothers Harriman & Co 2.93M $161.82M -3.2%
Dimensional Fund Advisors 2.79M $153.96M -9.0%
London Co Of Virginia 2.76M $152.57M +21.5%
Sound Shore Management 2.39M $132.04M -3.7%
Geode Capital Management 2.35M $129.59M +3.8%
Largest transactions
Shares Bought/sold Change
Clal Insurance Enterprises 1.52M +1.49M +4837.2%
Parnassus Investments 0 -1.16M EXIT
N Price T Rowe Associates 19.43M -993.91K -4.9%
Nuveen Asset Management 2.1M +949.79K +82.5%
Citadel Advisors 1.53M -946.85K -38.3%
AMP Ameriprise Financial 275.8K -743.08K -72.9%
First Trust Advisors 35.43K -606.81K -94.5%
London Co Of Virginia 2.76M +488.36K +21.5%
Alyeska Investment 125.02K -466.6K -78.9%
Alliancebernstein 2.15M +402.39K +23.1%

Financial report summary

?
Risks
  • We face vigorous competition from other pharmaceutical and consumer packaged goods companies that may threaten the commercial acceptance and pricing of our products.
  • If we do not continue to develop, manufacture, and market innovative products, introduce new line extensions, or expand into adjacent categories that meet customer demands, we may lose market share and our net sales may be negatively impacted.
  • We operate in highly regulated industries, and any inability to timely meet current or future regulatory requirements could have a material adverse effect on our business, financial position, and operating results.
  • Continuing healthcare reforms and related changes to reimbursement methods in and outside of the United States may have an adverse effect on our financial condition and results of operations.
  • If we fail to comply with the reporting and payment obligations under the Medicaid rebate program or other governmental purchasing and rebate programs, we could be subject to fines or penalties, which could have an adverse effect on our financial condition and results of operations.
  • Lack of availability, or significant increases in the cost, of raw materials used in manufacturing our products could adversely impact our profit margins and operating results.
  • A disruption at any of our main manufacturing facilities could materially and adversely affect our business, financial position, and results of operations.
  • Any breach, disruption or misuse of our or our external business partners’ information systems or cyber security efforts could have a material adverse effect on our business.
  • Our business depends upon certain customers for a significant portion of our sales, therefore our business would be adversely affected by a disruption of our relationship with these customers or any material adverse change in these customers' businesses.
  • We are dependent on the services of certain key members of management. Our inability to successfully manage transition, or the failure to attract and retain other key members of management, may have a material adverse impact on our results of operations.
  • Management transition creates uncertainties, and any difficulties we experience in managing such transitions may negatively impact our business.
  • Unfavorable publicity or consumer perception of the safety, quality, and efficacy of our products could have a material adverse impact on our business.
  • Our quarterly results are impacted by several factors, some of which are beyond the control of our management, that may result in significant quarter-to-quarter fluctuations in operating results.
  • We may not be able to sustain or improve operating results in our business segments.
  • We may not realize the benefits of business acquisitions and divestitures we enter into, which could have a material adverse effect on our operating results.
  • The plan to separate our RX business is contingent upon several conditions, is subject to change in form or timing, may not achieve the intended benefits, and could adversely affect our business and financial condition.
  • We have acquired significant assets that could become impaired or subject us to losses and may result in an adverse impact on our results of operations.
  • There can be no assurance that our strategic initiatives will achieve their intended effects.
  • While we have remediated previously identified material weaknesses in our internal control over financial reporting related to our income tax process, we may identify other material weaknesses in the future.
  • Our business, financial condition, and results of operations are subject to risks arising from the international scope of our operations.
  • We operate in jurisdictions that could be affected by economic and political instability, which could have a material adverse effect on our business.
  • The international scope of our business exposes us to risks associated with foreign exchange rates.
  • We are or may become involved in lawsuits and may experience unfavorable outcomes of such proceedings.
  • Increased scrutiny on pricing practices and competition in the pharmaceutical industry, including antitrust enforcement activity by government agencies and class action litigation, may have an adverse impact on our business and results of operations.
  • Publishing earnings guidance subjects us to risks, including increased stock volatility, that could lead to potential lawsuits by investors.
  • Third-party patents and other intellectual property rights may limit our ability to bring new products to market and may subject us to potential legal liability, causing us to incur significant costs.
  • The success of certain of our products depends on the effectiveness of measures we take to protect our intellectual property rights and patents.
  • Significant increases in the cost or decreases in the availability of the insurance we maintain could adversely impact our financial condition.
  • The resolution of uncertain tax positions, including the Notices of Proposed Adjustments and Notice of Assessment, could be unfavorable, which could have an adverse effect on our business.
  • The U.S. Internal Revenue Service ("IRS") may not agree with the conclusion that we are treated as a foreign corporation for U.S. federal tax purposes.
  • Changes to tax laws could have a material adverse effect on our results of operations and the ability to utilize cash in a tax efficient manner.
  • Our effective tax rate or cash tax payment requirements may change in the future, which could adversely impact our future results from operations.
  • Our indebtedness could adversely affect our ability to implement our strategic initiatives.
  • We cannot guarantee that we will buy back our ordinary shares pursuant to our announced share repurchase plan or that our share repurchase plan will enhance long-term shareholder value.
  • Any additional shares we may issue could dilute your ownership in the Company.
  • We are incorporated in Ireland; Irish law differs from the laws in effect in the United States and may afford less protection to, or otherwise adversely affect, our shareholders.
  • Irish law differs from the laws in effect in the U.S. with respect to defending unwanted takeover proposals and may give our Board of Directors less ability to control negotiations with hostile offerors.
  • We may be limited in our ability to pay dividends or repurchase shares in the future.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: absenteeism, Acetate, Adapalene, adhere, adherence, Alcohol, Ammonium, answer, assumption, awaiting, back, BCS, Beta, binding, brick, cal, Calcipotriene, cannabidiol, CBD, Ciclopirox, clinical, Clomipramine, Colorado, Comfort, contemplating, conversion, country, deferral, dermatology, Device, digestive, Dip, doctor, Doyle, eighty, electrolyte, enforceable, enterprise, entrance, Erythromycin, Esomeprazole, Ethinyl, EU, evidence, exact, expedited, Fargo, fewer, Fluocinolone, Fluocinonide, Fluticasone, foot, GBP, Gentamicin, Glimepiride, Griseofulvin, guaranteed, HCL, healthy, hemp, Imiquimod, imposed, indenture, injury, interrupted, Issuer, Katherine, Kazmira, Ketoconazole, Lactate, lag, led, leveraging, lived, lost, MDD, MDR, medical, Methazolamide, mortar, Mupirocin, narrow, NMSA, notification, Notified, nuisance, Olopatadine, Ontario, partnership, pendency, perpetual, Philadelphia, physical, posture, Pravastatin, precise, Prednisone, prepayment, Prochlorperazine, Promethazine, promissory, properly, Propionate, purpose, reclassification, reconfigure, redeem, redemption, regime, reliability, repayment, repeal, retire, reversal, rewarded, rigging, Rosemont, round, school, senior, Sherman, small, solution, stake, sued, temporarily, tetrahydrocannabinol, thereunder, traffic, trustee, unconditionally, unfiled, unsecured, violation, waiting, wave
Removed: ACO, affiliated, authorization, Chairman, chargeback, gain, identify, judge, Manning, measure, Napier, President, rebate, refinancing, representing, restatement, scope, staging, treble, undisclosed, unrelated, variety, Westchester